NY-OPENLINK
OpenLink, the global leader in trading and risk management solutions to the energy, commodities, corporate, and financial services industries, has today announced John O’Malley’s appointment as CEO, effective immediately. Mr. O’Malley takes over from Mark Greene who announced his intention to retire earlier this year. Mr. Greene will continue to serve on the OpenLink Board as an independent director.
Mr. O’Malley has successfully led several technology and private equity backed portfolio companies from start-up to maturity in growth markets. Most recently, Mr. O’Malley was an Operating Partner for Thoma Bravo after being hired as CEO of Digital Insight, a portfolio company that was acquired by NCR. Previously, he has held the role of CEO at Panini, a global provider of payment technology; Memento, a leader in enterprise fraud detection software; and Harland Financial Solutions, which under his leadership grew from a small subsidiary to one of the leading providers of financial technology in North America in just nine years.
A programmer by training, Mr. O’Malley has deep experience in technology, software product management and professional services. Mr. O’Malley has previously led global financial services and technology companies in treasury, capital markets, retail banking, payment processing, global finance and guidance systems in companies such as Fiserv, Hogan Systems, Lockheed Martin and J.H. Harland and Company.
David Tunnell, Chairman of OpenLink Board of Directors and a Managing Director at Hellman & Friedman said: “Under Mark Greene, OpenLink maintained its leading position in energy and commodities, diversified into adjacent markets, and deepened its reach into the corporate and financial services industries. With more than 30 years of financial technology and software experience and a track record of transformational success, we are delighted to have John lead the next phase of growth for OpenLink.”
John O’Malley, CEO, OpenLink, added: “I am extremely excited to have joined OpenLink, and looking forward to capitalizing on a number of initiatives and investments that are already in place. OpenLink is evolving. We are serving new and existing segments, with quicker time to value, industry best practice and packaged solutions, world-class quality software, robust partnership networks and deeper relationships with our clients. Backed by Hellman & Friedman we look forward to growing our leadership position and further leveraging our resources to fuel the future of the industries we serve.”
Mr. O’Malley has served as an advisor to Stanford University and currently serves on the boards of TravelClick and iPipeline. He has also been a board member at D&H, Netzee, and the Alcoholism Council of New York, a non-profit organization.
-ENDS-
About OpenLink
Founded in 1992, OpenLink (www.openlink.com ) is the global leader in Transaction Lifecycle Management (TLM) software for the commodity, energy and financial services industries. OpenLink's products address portfolio management, trading, risk management, and operations processing for both financial and physical assets.
Owned by leading private equity investment firm Hellman & Friedman, OpenLink is a global software and services business that has grown both organically and through strategic acquisitions, to achieve revenues in excess of $300 million. The company serves over 500 clients, including 12 of the world's largest commodity and energy companies, 9 of the largest financial institutions, and 13 of the largest central banks. OpenLink has 1,200 employees in 14 global offices on five continents, with headquarters outside New York City and field offices in Houston, Manhattan, London, Berlin, Vienna, Toronto, Tulsa, São Paulo, Mexico City, Bangalore, Singapore, Dubai and Sydney.
OpenLink has received numerous industry awards and recognition, including citations as the industry leader in Commodity/Energy Trading and Risk Management (C/ETRM) systems, and first-in-class ranking by Energy Risk magazine, with analyst firms Gartner and Chartis citing OpenLink as a leader in Financial platforms.
About Hellman & Friedman
Hellman & Friedman is a leading private equity investment firm with offices in San Francisco, New York, and London. Since its founding in 1984, H&F has raised over $35 billion of committed capital. The firm focuses on investing in superior business franchises and serving as a value-added partner to management in select industries including software, financial services, internet & media, business & information services, healthcare, energy & industrials and retail & consumer. For more information on Hellman & Friedman, please visit www.hf.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20151207005914/en/
Contact:
OpenLink
Michael Golding
Global Head of Public Relations
michael.golding@openlink.com
Mobile:
+44 (0)7766398912
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom